BIOMAT Database Logo BIOMAT Database Logo

Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo. 1998

J Duan, and M Liuzzi, and W Paris, and M Lambert, and C Lawetz, and N Moss, and J Jaramillo, and J Gauthier, and R Déziel, and M G Cordingley
Bio-Méga Research Division, Boehringer Ingelheim (Canada) Ltd., Laval, Québec, Canada. jduan@bio-mega.boehringer-ingelheim.ca

The present study reports the activity of BILD 1633 SE against acyclovir (ACV)-resistant herpes simplex virus (HSV) infections in athymic nude (nu/nu) mice. BILD 1633 SE is a novel peptidomimetic inhibitor of HSV ribonucleotide reductase (RR). In vitro, it is more potent than ACV against several strains of wild-type as well as ACV-resistant HSV mutants. Its in vivo activity was tested against cutaneous viral infections in athymic nude mice infected with the ACV-resistant isolates HSV type 1 (HSV-1) dlsptk and PAAr5, which contain mutations in the viral thymidine kinase gene and the polymerase gene, respectively. Following cutaneous infection of athymic nude mice, both HSV-1 dlsptk and PAAr5 induced significant, reproducible, and persistent cutaneous lesions that lasted for more than 2 weeks. A 10-day treatment regimen with ACV given topically four times a day as a 5% cream or orally at up to 5 mg/ml in drinking water was partially effective against HSV-1 PAAr5 infection with a reduction of the area under the concentration-time curve (AUC) of 34 to 48%. The effects of ACV against HSV-1 dlsptk infection were not significant when it was administered topically and were only marginal when it was given in drinking water. Treatment under identical conditions with 5% topical BILD 1633 SE significantly reduced the cutaneous lesions caused by both HSV-1 dlsptk and PAAr5 infections. The effect of BILD 1633 SE against HSV-1 PAAr5 infections was more prominent and was inoculum and dose dependent, with AUC reductions of 96 and 67% against infections with 10(6) and 10(7) PFU per inoculation site, respectively. BILD 1633 SE also significantly decreased the lesions caused by HSV-1 dlsptk infection (28 to 51% AUC reduction). Combination therapy with topical BILD 1633 SE (5%) and ACV in drinking water (5 mg/ml) produced an antiviral effect against HSV-1 dlsptk and PAAr5 infections that was more than the sum of the effects of both drugs. This is the first report that a selective HSV RR subunit association inhibitor can be effective against ACV-resistant HSV infections in vivo.

UI MeSH Term Description Entries
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005260 Female Females
D006561 Herpes Simplex A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.) Herpes Simplex Virus Infection
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000212 Acyclovir A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. Acycloguanosine,9-((2-Hydroxyethoxy)methyl)guanine,Aci-Sanorania,Acic,Aciclobeta,Aciclostad,Aciclovir,Aciclovir Alonga,Aciclovir-Sanorania,Acifur,Acipen Solutab,Acivir,Activir,Acyclo-V,Acyclovir Sodium,Antiherpes Creme,Avirax,Cicloferon,Clonorax,Cusiviral,Genvir,Herpetad,Herpofug,Herpotern,Herpoviric,Isavir,Laciken,Mapox,Maynar,Milavir,Opthavir,Supraviran,Viclovir,Vipral,Virax-Puren,Virherpes,Virmen,Virolex,Virupos,Virzin,Wellcome-248U,Zoliparin,Zovirax,Zyclir,aciclovir von ct,Aci Sanorania,Aciclovir Sanorania,Acyclo V,Alonga, Aciclovir,Sodium, Acyclovir,Solutab, Acipen,Virax Puren,ViraxPuren,Wellcome 248U,Wellcome248U
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations

Related Publications

J Duan, and M Liuzzi, and W Paris, and M Lambert, and C Lawetz, and N Moss, and J Jaramillo, and J Gauthier, and R Déziel, and M G Cordingley
Antiviral screening of four plant extracts against acyclovir resistant herpes simplex virus type-1.
July 2017, Pakistan journal of pharmaceutical sciences,
J Duan, and M Liuzzi, and W Paris, and M Lambert, and C Lawetz, and N Moss, and J Jaramillo, and J Gauthier, and R Déziel, and M G Cordingley
Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir.
May 1992, Antimicrobial agents and chemotherapy,
J Duan, and M Liuzzi, and W Paris, and M Lambert, and C Lawetz, and N Moss, and J Jaramillo, and J Gauthier, and R Déziel, and M G Cordingley
Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase with improved in vivo antiviral activity.
October 1996, Journal of medicinal chemistry,
J Duan, and M Liuzzi, and W Paris, and M Lambert, and C Lawetz, and N Moss, and J Jaramillo, and J Gauthier, and R Déziel, and M G Cordingley
Antiviral activity of Viracea against acyclovir susceptible and acyclovir resistant strains of herpes simplex virus.
July 1998, Antiviral research,
J Duan, and M Liuzzi, and W Paris, and M Lambert, and C Lawetz, and N Moss, and J Jaramillo, and J Gauthier, and R Déziel, and M G Cordingley
The effects of interferon-alpha and acyclovir on herpes simplex virus type-1 ribonucleotide reductase.
May 1998, Antiviral research,
J Duan, and M Liuzzi, and W Paris, and M Lambert, and C Lawetz, and N Moss, and J Jaramillo, and J Gauthier, and R Déziel, and M G Cordingley
Synthetic pregnenolone derivatives as antiviral agents against acyclovir-resistant isolates of Herpes Simplex Virus Type 1.
October 2015, Antiviral research,
J Duan, and M Liuzzi, and W Paris, and M Lambert, and C Lawetz, and N Moss, and J Jaramillo, and J Gauthier, and R Déziel, and M G Cordingley
In vivo antiviral activity of Stephania cepharantha against herpes simplex virus type-1.
September 2001, Phytotherapy research : PTR,
J Duan, and M Liuzzi, and W Paris, and M Lambert, and C Lawetz, and N Moss, and J Jaramillo, and J Gauthier, and R Déziel, and M G Cordingley
Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir.
August 1989, Antimicrobial agents and chemotherapy,
J Duan, and M Liuzzi, and W Paris, and M Lambert, and C Lawetz, and N Moss, and J Jaramillo, and J Gauthier, and R Déziel, and M G Cordingley
Ribonucleotide reductase of herpes simplex virus type 2 resembles that of herpes simplex virus type 1.
December 1984, Journal of virology,
J Duan, and M Liuzzi, and W Paris, and M Lambert, and C Lawetz, and N Moss, and J Jaramillo, and J Gauthier, and R Déziel, and M G Cordingley
Potential for combined therapy with 348U87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir-resistant herpes simplex virus infection.
January 1993, Journal of medical virology,
Copied contents to your clipboard!